LFMDP — LifeMD, Inc.

LifeMD (LFMDP) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $46.9 million, up 4% year-over-year.
• Full Year Revenue: $194.1 million, a 25% increase from 2024.
• Active Subscribers: 322,000 at quarter-end, a 16% year-over-year increase.
• Gross Margin: 87.1% for Q4, up 570 basis points year-over-year; 85.7% for the full year, a slight decrease of 50 basis points.
• GAAP Net Income: $19 million for Q4 ($0.41 per share), including a one-time gain from the sale of WorkSimpli; adjusted net loss from continuing operations was $1.9 million ($0.04 per share).
• Adjusted EBITDA: $4.8 million for Q4, up from $1.1 million in the prior year; $15.3 million for the full year, compared to $3.7 million in 2024.
• Cash Position: $36.8 million with no debt.

2. Strategic Updates and Business Highlights

• Subscriber Growth: Added over 13,000 net new subscribers in Q4, the largest gain of 2025.
• Weight Management: Record patient acquisition with nearly 700 new sign-ups per day; launched oral Wegovy in collaboration with Novo Nordisk.
• Women's Health Initiative: Significant investment in this area, including the acquisition of Optimal Human Health and partnerships with recognized experts in women's health.
• Men's Health: RexMD brand returned to growth, with plans to expand offerings into new therapeutic areas.
• Pharmacy Operations: Now licensed in all 50 states, processing approximately 20,000 prescriptions monthly; 70% of fulfillment handled in-house, providing flexibility and margin improvement.
• AI Integration: Focus on deploying AI across care delivery and operational workflows to enhance efficiency and patient outcomes.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Guidance: Expected between $48 million and $49 million, with an adjusted EBITDA loss projected between $4 million and $5 million due to increased investments in patient acquisition.
• Full Year 2026 Revenue Guidance: Anticipated between $220 million and $230 million, with adjusted EBITDA expected between $12 million and $17 million.
• Long-term Growth: By Q4 2026, expected annualized revenue run rate to exceed $250 million, with adjusted EBITDA exceeding $25 million.

4. Bad News, Challenges, or Points of Concern

• Net Loss from Continuing Operations: Despite a strong revenue increase, the company reported a net loss of $1.9 million in Q4 when excluding one-time gains.
• Early Stage Women's Health Offering: While promising, it is not expected to be EBITDA positive in its first year, which may impact overall profitability.
• Competitive Pressures: New entrants like Amazon and Lilly in the weight management space could pose challenges to market share and pricing strategies.
• Retention Rates: While initial retention rates for the Wegovy pill are promising, long-term retention remains uncertain.

5. Notable Q&A Insights

• Demand for Wegovy: Strong demand noted for the oral Wegovy pill, with significant increases in new patient acquisition compared to previous quarters.
• Unit Economics: Gross margins for Wegovy are healthy, with margins around $100 per order, primarily driven by additional services rather than the product itself.
• Insurance Coverage Impact: The company is optimistic about expanding insurance coverage, which could enhance patient retention and lower customer acquisition costs.
• Marketing Strategy: Continued focus on existing channels with new partnerships yielding promising results; potential for transformational partnerships in the pipeline.

Overall, LifeMD demonstrated strong performance in Q4 2025, with a solid financial position and strategic initiatives aimed at long-term growth, despite facing challenges from competition and the nascent stage of some business segments.